Dynamics of Naturally-Acquired Immunity Against SARS-CoV-2 in Children and Adolescents

[1]  J. Stowe,et al.  Protection against symptomatic disease with the delta and omicron BA.1/BA.2 variants of SARS-CoV-2 after infection and vaccination in adolescents: national observational test-negative case control study, August 2021 to March 2022, England , 2022, medRxiv.

[2]  S. Hoehl,et al.  Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5 , 2022, bioRxiv.

[3]  V. Pitzer,et al.  Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study , 2022, BMJ.

[4]  R. Iachan,et al.  Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[5]  E. Herzel,et al.  SARS-CoV-2 Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: a Retrospective Cohort Study. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  V. Pitzer,et al.  Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in Israel , 2022, medRxiv.

[7]  S. Ladhani,et al.  Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England , 2022, The Lancet Child & Adolescent Health.

[8]  Y. Maor,et al.  Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine , 2022, Nature Communications.

[9]  Gheyath K Nasrallah,et al.  Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.

[10]  Gheyath K Nasrallah,et al.  Protection against the Omicron Variant from Previous SARS-CoV-2 Infection , 2022, The New England journal of medicine.

[11]  Gheyath K Nasrallah,et al.  Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections , 2022, Nature communications.

[12]  E. Harris,et al.  Burden of SARS-CoV-2 and protection from symptomatic second infection in children , 2022, medRxiv.

[13]  John Wright,et al.  Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection , 2021, Nature immunology.

[14]  Y. Kreiss,et al.  Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection , 2021, medRxiv.

[15]  Michael I. Mandel,et al.  Protection and waning of natural and hybrid COVID-19 immunity , 2021, medRxiv.

[16]  S. Kannan,et al.  Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. , 2021, European review for medical and pharmacological sciences.

[17]  D. Weinberger,et al.  Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. , 2021, JAMA internal medicine.

[18]  Michael I. Mandel,et al.  Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.

[19]  Michael I. Mandel,et al.  Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.

[20]  N. Dean,et al.  Covid-19 Vaccine Effectiveness and the Test-Negative Design , 2021, The New England journal of medicine.

[21]  L. Abu-Raddad,et al.  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.

[22]  A. Fontanet,et al.  Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection , 2021, EBioMedicine.

[23]  B. Mizrahi,et al.  Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine , 2021, Nature Communications.

[24]  K. Bruxvoort,et al.  Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients , 2021, Clinical Microbiology and Infection.

[25]  Mattia G. Bergomi,et al.  Mapping the human genetic architecture of COVID-19 , 2021, Nature.

[26]  F. Krammer.  A correlate of protection for SARS-CoV-2 vaccines is urgently needed , 2021, Nature Medicine.

[27]  C. Rice,et al.  Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.

[28]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[29]  K. Mølbak,et al.  Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study , 2021, The Lancet.

[30]  G. Chodick,et al.  A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report , 2021, medRxiv.

[31]  D. Stuart,et al.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.

[32]  A. Iwasaki.  What reinfections mean for COVID-19 , 2020, The Lancet Infectious Diseases.

[33]  J. Tang,et al.  Setting the criteria for SARS-CoV-2 reinfection – six possible cases , 2020, Journal of Infection.

[34]  G. Chodick,et al.  Prevalence and Factors Associated With Resistant Hypertension in a Large Health Maintenance Organization in Israel , 2014, Hypertension.

[35]  J. Coresh,et al.  Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. , 2014, JAMA.

[36]  G. Chodick,et al.  The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. , 2011, International journal of cardiology.

[37]  G. Chodick,et al.  The epidemiology of diabetes in a large Israeli HMO , 2002, European Journal of Epidemiology.